We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
-3.39%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$2.6B
AUM Growth
+$272M
Cap. Flow
+$580M
Cap. Flow %
22.28%
Top 10 Hldgs %
59.11%
Holding
341
New
89
Increased
83
Reduced
62
Closed
85

Top Buys

Rank Stock Value
1
ACHC icon
Acadia Healthcare
ACHC
+$32.4M
2
AZN icon
AstraZeneca
AZN
+$11.6M
3
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$10.4M
4
QRHC icon
Quest Resource Holding
QRHC
+$8.96M
5
MBOT icon
Microbot Medical
MBOT
+$7.86M

Top Sells

Rank Stock Value
1
WY icon
Weyerhaeuser
WY
+$64.6M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$53.7M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$16.1M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$13.3M
5
OPK icon
Opko Health
OPK
+$10.5M

Sector Composition

Rank Sector Weight
1 Miscellaneous 92.32%
2 Healthcare 6.56%
3 Energy 0.47%
4 Consumer Discretionary 0.36%
5 Industrials 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PLUR icon
151
PUT
Pluri
PLUR
$14.4M
$943K 0.04%
41
-1
-2% -$228
ARCT icon
152
CALL
Arcturus Therapeutics
ARCT
$447M
$900K 0.03%
+83
New +$10.8K
SRPT icon
153
PUT
Sarepta Therapeutics
SRPT
$2.19B
$893K 0.03%
423
-1,270
-75% -$28.7K
BLUE
154
DELISTED
bluebird bio
BLUE
$882K 0.03%
+1,897
New +$875K
DYAX
155
CALL
DELISTED
DYAX CORPORATION
DYAX
$882K 0.03%
+872
New +$8.45K
CVM.WS
156
DELISTED
Cel-Sci Corp Series S
CVM.WS
$874K 0.03%
3,972,437
-876,563
-18% -$223K
VNDA icon
157
Vanda Pharmaceuticals
VNDA
$300M
$847K 0.03%
81,600
-48,400
-37% -$634K
SCTL
158
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$821K 0.03%
309,415
+100,977
+48% +$491K
ACGN
159
CALL
DELISTED
Aceragen Inc
ACGN
$808K 0.03%
+3
New +$8.64K
CORI
160
DELISTED
Corium International, Inc.
CORI
$803K 0.03%
130,732
-1,990
-1% -$13.2K
SMLR
161
DELISTED
Semler Scientific
SMLR
$789K 0.03%
281,951
-52,087
-16% -$186K
SGEN
162
CALL
DELISTED
Seagen Inc. Common Stock
SGEN
$784K 0.03%
211
– –
CEMP
163
DELISTED
Cempra, Inc.
CEMP
$776K 0.03%
70,804
-78,196
-52% -$770K
EIGR
164
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$743K 0.03%
+158
New +$835K
TNXP icon
165
PUT
Tonix Pharmaceuticals
TNXP
$200M
– –
0
– –
MDGN.WS
166
DELISTED
MEDGENICS INC WT PUR COM EXP 03/31/16
MDGN.WS
$673K 0.03%
841,712
+11,400
+1% +$19.2K
VIRX
167
PUT
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$650K 0.03%
4
-1
-20% -$1.45K
RCPT
168
CALL
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$627K 0.02%
+101
New +$4.83K
QURE icon
169
uniQure
QURE
$2.99B
$620K 0.02%
67,313
-157,768
-70% -$1.73M
RXII
170
DELISTED
GALENA BIOPHARMA INC COM
RXII
$582K 0.02%
282,704
+17,354
+7% +$35.7K
ACHN
171
DELISTED
Achillion Pharmaceuticals
ACHN
$579K 0.02%
+57,971
New +$538K
NBSE
172
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
$575K 0.02%
198
-49
-20% -$162K
NURO
173
DELISTED
NeuroMetrix, Inc. Common Stock
NURO
$561K 0.02%
122
+77
+171% +$359K
ECYT
174
PUT
DELISTED
Endocyte, Inc. Common Stock
ECYT
$525K 0.02%
863
– –
ENTA icon
175
CALL
Enanta Pharmaceuticals
ENTA
$356M
$514K 0.02%
130
+28
+27% +$1.12K
5 6
7
8 9

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q3 2014 Portfolio in Review

As of Q3 2014, Sabby Management held 341 positions worth $2.6B, up 12% from $2.33B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Sabby Management deployed $580M of net new capital in Q3 2014, opening 89 new positions and adding to 83 existing holdings. Its largest new stake was Acadia Healthcare: 663,324 shares worth $16.4M.

By sector, the portfolio is most concentrated in Miscellaneous at 92% of assets, up from 87% a quarter earlier, followed by Healthcare and Energy.

On the sell side, the largest reduction was SALIX PHARMACEUTICALS LTD DEL, an estimated $6.87M trimmed.

  • Sabby Management's largest Q3 2014 buy was Acadia Healthcare: 663,324 shares worth $16.4M.
  • Sabby Management added most to AstraZeneca in Q3 2014, an estimated $11.6M increase.
  • Sabby Management's biggest Q3 2014 reduction was SALIX PHARMACEUTICALS LTD DEL, cutting an estimated $6.87M.
  • Sabby Management fully exited Weyerhaeuser in Q3 2014, selling an estimated $64.6M.
  • Sabby Management's ten largest holdings make up 59% of its $2.6B portfolio in Q3 2014.
  • Sabby Management opened 89 new positions and closed 85 in Q3 2014.
  • Sabby Management's portfolio value rose 12% quarter-over-quarter to $2.6B.

Based on Sabby Management's 13F filing for Q3 2014, filed 14 Nov 2014.